These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 35941226)

  • 1. The efficacy of selinexor (KPT-330), an XPO1 inhibitor, on non-hematologic cancers: a comprehensive review.
    Landes JR; Moore SA; Bartley BR; Doan HQ; Rady PL; Tyring SK
    J Cancer Res Clin Oncol; 2023 May; 149(5):2139-2155. PubMed ID: 35941226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical antitumor efficacy of selective exportin 1 inhibitors in glioblastoma.
    Green AL; Ramkissoon SH; McCauley D; Jones K; Perry JA; Hsu JH; Ramkissoon LA; Maire CL; Hubbell-Engler B; Knoff DS; Shacham S; Ligon KL; Kung AL
    Neuro Oncol; 2015 May; 17(5):697-707. PubMed ID: 25366336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Implications of Targeting XPO1-mediated Nuclear Export in Multiple Myeloma.
    Gandhi UH; Senapedis W; Baloglu E; Unger TJ; Chari A; Vogl D; Cornell RF
    Clin Lymphoma Myeloma Leuk; 2018 May; 18(5):335-345. PubMed ID: 29610030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selinexor, selective inhibitor of nuclear export: Unselective bullet for blood cancers.
    Benkova K; Mihalyova J; Hajek R; Jelinek T
    Blood Rev; 2021 Mar; 46():100758. PubMed ID: 32972802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. XPO1/CRM1-selective inhibitors of nuclear export (SINE) reduce tumor spreading and improve overall survival in preclinical models of prostate cancer (PCa).
    Gravina GL; Tortoreto M; Mancini A; Addis A; Di Cesare E; Lenzi A; Landesman Y; McCauley D; Kauffman M; Shacham S; Zaffaroni N; Festuccia C
    J Hematol Oncol; 2014 Oct; 7():46. PubMed ID: 25284315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-tumor efficacy of Selinexor (KPT-330) in gastric cancer is dependent on nuclear accumulation of p53 tumor suppressor.
    Subhash VV; Yeo MS; Wang L; Tan SH; Wong FY; Thuya WL; Tan WL; Peethala PC; Soe MY; Tan DSP; Padmanabhan N; Baloglu E; Shacham S; Tan P; Koeffler HP; Yong WP
    Sci Rep; 2018 Aug; 8(1):12248. PubMed ID: 30115935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone.
    Muqbil I; Aboukameel A; Elloul S; Carlson R; Senapedis W; Baloglu E; Kauffman M; Shacham S; Bhutani D; Zonder J; Azmi AS; Mohammad RM
    Cancer Lett; 2016 Dec; 383(2):309-317. PubMed ID: 27693556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A method for quantification of exportin-1 (XPO1) occupancy by Selective Inhibitor of Nuclear Export (SINE) compounds.
    Crochiere ML; Baloglu E; Klebanov B; Donovan S; Del Alamo D; Lee M; Kauffman M; Shacham S; Landesman Y
    Oncotarget; 2016 Jan; 7(2):1863-77. PubMed ID: 26654943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SINE (selective inhibitor of nuclear export)--translational science in a new class of anti-cancer agents.
    Gerecitano J
    J Hematol Oncol; 2014 Oct; 7():67. PubMed ID: 25281264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors.
    Turner JG; Dawson JL; Grant S; Shain KH; Dalton WS; Dai Y; Meads M; Baz R; Kauffman M; Shacham S; Sullivan DM
    J Hematol Oncol; 2016 Aug; 9(1):73. PubMed ID: 27557643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-κB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death.
    Kashyap T; Argueta C; Aboukameel A; Unger TJ; Klebanov B; Mohammad RM; Muqbil I; Azmi AS; Drolen C; Senapedis W; Lee M; Kauffman M; Shacham S; Landesman Y
    Oncotarget; 2016 Nov; 7(48):78883-78895. PubMed ID: 27713151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study.
    Thein KZ; Piha-Paul SA; Tsimberidou A; Karp DD; Janku F; Zarifa A; Shah J; Milton DR; Bean S; McQuinn L; Gong J; Colen R; Carter BW; Subbiah V; Ogbonna DC; Pant S; Meric-Bernstam F; Naing A
    Invest New Drugs; 2021 Oct; 39(5):1357-1365. PubMed ID: 33909232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): A report from the pediatric preclinical testing program.
    Attiyeh EF; Maris JM; Lock R; Reynolds CP; Kang MH; Carol H; Gorlick R; Kolb EA; Keir ST; Wu J; Landesman Y; Shacham S; Lyalin D; Kurmasheva RT; Houghton PJ; Smith MA
    Pediatr Blood Cancer; 2016 Feb; 63(2):276-86. PubMed ID: 26398108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma.
    Turner JG; Kashyap T; Dawson JL; Gomez J; Bauer AA; Grant S; Dai Y; Shain KH; Meads M; Landesman Y; Sullivan DM
    Oncotarget; 2016 Nov; 7(48):78896-78909. PubMed ID: 27806331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selinexor: A First-in-Class Nuclear Export Inhibitor for Management of Multiply Relapsed Multiple Myeloma.
    Peterson TJ; Orozco J; Buege M
    Ann Pharmacother; 2020 Jun; 54(6):577-582. PubMed ID: 31793336
    [No Abstract]   [Full Text] [Related]  

  • 16. E3 ubiquitin ligase ASB8 promotes selinexor-induced proteasomal degradation of XPO1.
    Kwanten B; Deconick T; Walker C; Wang F; Landesman Y; Daelemans D
    Biomed Pharmacother; 2023 Apr; 160():114305. PubMed ID: 36731340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deciphering mechanisms of drug sensitivity and resistance to Selective Inhibitor of Nuclear Export (SINE) compounds.
    Crochiere M; Kashyap T; Kalid O; Shechter S; Klebanov B; Senapedis W; Saint-Martin JR; Landesman Y
    BMC Cancer; 2015 Nov; 15():910. PubMed ID: 26573568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selinexor for the treatment of patients with previously treated multiple myeloma.
    Mo CC; Jagannath S; Chari A; Nooka AK; Lonial S; Siegel D; Biran N; Gasparetto C; Bahlis NJ; Richardson P
    Expert Rev Hematol; 2021 Aug; 14(8):697-706. PubMed ID: 33985401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selinexor in multiple myeloma.
    Martino EA; Vigna E; Bruzzese A; Labanca C; Mendicino F; Lucia E; Olivito V; Zimbo A; Torricelli F; Neri A; Morabito F; Gentile M
    Expert Opin Pharmacother; 2024 Mar; 25(4):421-434. PubMed ID: 38503547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selinexor for advanced hematologic malignancies.
    Walker JS; Garzon R; Lapalombella R
    Leuk Lymphoma; 2020 Oct; 61(10):2335-2350. PubMed ID: 32536290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.